Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03708003
Recruitment Status : Active, not recruiting
First Posted : October 16, 2018
Last Update Posted : August 31, 2020
Sponsor:
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : April 2028
Estimated Study Completion Date : December 2028